Key Ideas

Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors. A patient with metastatic pleomorphic dermal sarcoma achieved a near-complete response to pembrolizumab that has been sustained for eight months, illustrating why this high-mutation-burden sarcoma may respond unusually well to checkpoint inhibition, even though it lacks its own dedicated clinical trials or NCCN treatment category.

A Rare Diagnosis Hiding in Plain Sight

An older man with decades of unprotected sun exposure developed a left facial mass in 2023. What was initially removed as an atypical spindle cell tumor recurred locally, and after wide excision the pathology was reclassified as pleomorphic sarcoma with positive margins; he went on to receive adjuvant radiation. About a year later, surveillance imaging showed new bilateral lung masses, and a biopsy confirmed metastatic pleomorphic sarcoma. He started pembrolizumab, and within four months, imaging showed resolution of the previously intensely metabolically active lung metastases, with the response sustained at eight months on further imaging.

Why This Sarcoma Behaves Differently

Pleomorphic dermal sarcoma (PDS) is a rare, UV-driven fibroblastic malignancy arising in chronically sun-damaged skin, most often the head, neck, and scalp of older men. It was historically grouped with related entities like atypical fibroxanthoma (a more indolent lesion on the same biological spectrum) and undifferentiated pleomorphic sarcoma of the skin. PDS and its relatives share recurrent alterations in TP53 and CDKN2A, but what makes PDS clinically distinctive is the sheer volume of UV-induced mutations it carries: tumor mutational burden in this case fell in the range of 50 to 60 mutations per megabase, among the higher levels seen in any solid tumor. That mutational load, combined with dense infiltration by tumor-fighting immune cells and expression of PD-L1 and LAG3, makes PDS biologically primed to respond to immune checkpoint blockade, even though it is officially classified only under the broader category of metastatic soft tissue sarcoma, with no PDS-specific NCCN guidance or dedicated clinical trials.

Diagnosis itself is often a challenge, since PDS can resemble other spindle cell malignancies, including melanoma, sarcomatoid carcinoma, and leiomyosarcoma, and typically requires staining for cytokeratins and other markers to rule those out.

What the Broader Evidence Suggests

Because no trials specifically enroll PDS, the supporting evidence comes from related undifferentiated pleomorphic sarcoma (UPS) trials and from case reports. A phase 2 study of pembrolizumab in UPS (SARC028) reported an objective response rate around 23 percent with a median duration of response of about 49 weeks, and a separate Alliance trial combining nivolumab with or without ipilimumab also showed meaningful activity in UPS. The current patient's near-complete, sustained response is consistent with the idea that PDS, given its especially high mutational burden and inflamed tumor microenvironment, may respond even more favorably than UPS as a whole, though this remains anecdotal until larger series accumulate.

Access to pembrolizumab for this indication is not automatic: it required active advocacy with the patient's insurer, including citation of case reports and direct conversations with the payer, since PDS carries no formal approval for checkpoint inhibition.

For Patients

If you or a loved one has a skin lesion on a chronically sun-exposed area, especially the head, neck, or scalp of an older adult, that turns out to be a rare spindle cell sarcoma, ask specifically about pleomorphic dermal sarcoma as a possible diagnosis, since it can be confused with other tumor types on initial biopsy. If metastatic disease is confirmed, ask your oncologist about genetic testing of the tumor, including tumor mutational burden and microsatellite instability status, since a high mutational burden supports the case for immunotherapy such as pembrolizumab even in the absence of an official approval for this specific cancer type. Be prepared that insurance approval may take extra effort from your care team, since this use is technically off-label; that reflects how rare and recently characterized this cancer is, not a lack of supporting evidence.

Key Takeaways

  • Pleomorphic dermal sarcoma is a rare, UV-driven skin cancer arising on chronically sun-damaged skin, most common in older men.

  • It carries an unusually high tumor mutational burden, which likely explains why checkpoint inhibitors such as pembrolizumab can produce deep, durable responses.

  • There is no PDS-specific NCCN treatment category or dedicated clinical trial; treatment decisions currently draw on related sarcoma trials and case-level evidence.

  • In this case, metastatic disease achieved a near-complete, sustained response to pembrolizumab, supporting consideration of checkpoint inhibition early in metastatic PDS.

  • Diagnosis can be difficult and often requires additional immunostaining to distinguish PDS from other spindle cell malignancies.

References

  1. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology.

  2. D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401). Lancet Oncology.